ADAR1 Capital Management LLC Boosts Holdings in Delcath Systems, Inc. (NASDAQ:DCTH)

ADAR1 Capital Management LLC raised its stake in Delcath Systems, Inc. (NASDAQ:DCTH) by 381.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 149,385 shares of the company’s stock after acquiring an additional 118,333 shares during the quarter. ADAR1 Capital Management LLC owned approximately 0.47% of Delcath Systems worth $1,799,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Geode Capital Management LLC grew its holdings in Delcath Systems by 14.7% during the fourth quarter. Geode Capital Management LLC now owns 288,951 shares of the company’s stock valued at $3,481,000 after purchasing an additional 37,056 shares during the period. Principal Financial Group Inc. increased its holdings in Delcath Systems by 28.8% in the 4th quarter. Principal Financial Group Inc. now owns 115,183 shares of the company’s stock worth $1,387,000 after acquiring an additional 25,736 shares during the last quarter. Diametric Capital LP lifted its holdings in Delcath Systems by 39.6% during the fourth quarter. Diametric Capital LP now owns 94,737 shares of the company’s stock valued at $1,141,000 after purchasing an additional 26,881 shares during the last quarter. State Street Corp boosted its position in Delcath Systems by 12.4% during the third quarter. State Street Corp now owns 85,457 shares of the company’s stock worth $772,000 after purchasing an additional 9,400 shares during the period. Finally, ExodusPoint Capital Management LP raised its position in shares of Delcath Systems by 32.2% in the fourth quarter. ExodusPoint Capital Management LP now owns 51,697 shares of the company’s stock valued at $622,000 after purchasing an additional 12,604 shares during the period. 61.12% of the stock is owned by institutional investors.

Delcath Systems Stock Down 8.3 %

DCTH opened at $11.01 on Monday. The stock has a market cap of $367.77 million, a PE ratio of -8.16 and a beta of 0.85. The business’s fifty day simple moving average is $14.28 and its 200 day simple moving average is $12.14. Delcath Systems, Inc. has a 52 week low of $4.26 and a 52 week high of $16.97.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). The company had revenue of $15.10 million for the quarter, compared to analysts’ expectations of $14.96 million. Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. During the same period last year, the company posted ($0.48) EPS. As a group, equities analysts anticipate that Delcath Systems, Inc. will post -0.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on DCTH. HC Wainwright raised their price objective on shares of Delcath Systems from $22.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, March 7th. Craig Hallum boosted their price objective on Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Friday, January 17th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $22.75.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.